



SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

INTERIM FINANCIAL STATEMENTS FOR THE 1ST HALF YEAR ENDED 30 JUNE 2024

CHARACTERISTICS OF THE LEAP MARKET OF BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”)

THE LEAP MARKET HAS BEEN POSITIONED AS A MARKET DESIGNED TO ACCOMMODATE CORPORATIONS TO WHICH A HIGHER INVESTMENT RISK MAY BE ATTACHED THAN OTHER CORPORATIONS LISTED ON THE ACE MARKET OR MAIN MARKET OF BURSA SECURITIES. IT IS A QUALIFIED MARKET WHICH IS MEANT MAINLY FOR SOPHISTICATED INVESTORS ONLY. ONLY EXISTING SECURITIES HOLDERS AND SOPHISTICATED INVESTORS ARE ALLOWED TO PARTICIPATE IN CORPORATE EXERCISES UNDERTAKEN BY SUPERGENICS BERHAD (“SGBHD” OR THE “COMPANY”). SOPHISTICATED INVESTORS SHOULD BE AWARE OF THE POTENTIAL RISKS OF INVESTING IN SUCH CORPORATIONS AND SHOULD MAKE THE DECISION TO INVEST ONLY AFTER DUE AND CAREFUL CONSIDERATION.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1ST HALF YEAR ENDED 30 JUNE 2024

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	INDIVIDUAL		CUMULATIVE	
	6 Months Ended		Year To Date	
	30 Jun 2024	30 Jun 2023	30 Jun 2024	30 Jun 2023
	RM'000	RM'000	RM'000	RM'000
Revenue	2,770	4,490	2,770	4,490
Cost of sales	(1,633)	(2,780)	(1,633)	(2,780)
Gross profit	1,137	1,710	1,137	1,710
Other operating income	148	362	148	362
Operating and administrative expenses	(2,178)	(1,705)	(2,178)	(1,705)
(Loss)/Profit from operations	(893)	367	(893)	367
Finance costs	(230)	(206)	(230)	(206)
(Loss)/Profit before taxation	(1,123)	161	(1,123)	161
Taxation	127	(114)	127	(114)
Total comprehensive (Loss)/Profit	(996)	47	(996)	47
Total comprehensive (Loss)/Profit attributable to :				
Owners of the parent	(988)	47	(988)	47
Non-controlling interests	(8)	-	(8)	-
	(996)	47	(996)	47
(Loss)/Earning per-share	sen	sen	sen	sen
Basic	(0.87)	0.05	(0.87)	0.05
Diluted	N/A	N/A	N/A	N/A

The Condensed Consolidated Statement of Profit or Loss and Other Comprehensive income should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2023.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1ST HALF YEAR ENDED 30 JUNE 2024

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	(UNAUDITED) As At 30 Jun 2024 RM'000	(AUDITED) As At 31 Dec 2023 RM'000
ASSETS		
NON-CURRENT ASSETS		
Property, plant and equipment	4,290	4,218
Right-of-use assets	1,634	1,735
Investment in associate	31	31
Intangible asset	1,268	582
Contract assets	46	117
	7,269	6,683
CURRENT ASSETS		
Trade receivables	6,218	8,834
Other receivables, deposits and prepayments	4,349	922
Other financial assets	167	83
Contract assets	158	173
Tax recoverable	112	-
Cash and bank balances	1,720	2,700
	12,724	12,712
TOTAL ASSETS	19,993	19,395
EQUITY		
Share capital	11,664	9,777
Merger reserve	(1,450)	(1,450)
Foreign currency reserve	-	1
Retained (loss)/earnings	(621)	367
	9,593	8,695
Non-controlling Interests	(35)	(27)
Total Equity	9,558	8,668
LIABILITIES		
NON-CURRENT LIABILITIES		
Deferred tax liabilities	140	140
Lease liabilities	1,253	1,388
Bank borrowings	2,258	2,347
	3,651	3,875
CURRENT LIABILITIES		
Trade payables	709	1,767
Other payables and accruals	3,509	3,466
Contract liabilities	216	-
Amount owing to directors	8	-
Lease liabilities	378	327
Bank borrowings	1,964	1,066
Provision for taxation	-	226
	6,784	6,852
TOTAL LIABILITIES	10,435	10,727
TOTAL EQUITY AND LIABILITIES	19,993	19,395
NET ASSETS PER-SHARE (RM)	0.084	0.092

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2023.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1ST HALF YEAR ENDED 30 JUNE 2024
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

GROUP	← ATTRIBUTABLE TO THE OWNERS OF THE PARENT →						Non-controlling Interests RM'000	TOTAL EQUITY RM'000
	Non-distributable			Distributable		TOTAL RM'000		
	Share Capital RM'000	Merger Reserve RM'000	Foreign Currency Translation Reserve RM'000	Retained Earnings/(Loss) RM'000				
As at 1 Jan 2024	9,777	(1,450)	1	367	8,695	(27)	8,668	
Total comprehensive loss for the financial year	-	-	-	(988)	(988)	(8)	(996)	
Other comprehensive loss	-	-	(1)	-	(1)	-	(1)	
Transactions with owners:-								
Issuance of ordinary shares	1,900	-	-	-	1,900	-	1,900	
Share issuance expenses	(13)	-	-	-	(13)	-	(13)	
Total transactions with owners	1,887	-	-	-	1,887	-	1,887	
As at 30 Jun 2024	11,664	(1,450)	-	(621)	9,593	(35)	9,558	
As at 1 Jan 2023	6,302	(1,450)	-	190	5,042	-	5,042	
Total comprehensive income for the financial year	-	-	-	177	177	(29)	148	
Foreign currency translation differences	-	-	1	-	1	-	1	
Transactions with owners:-								
Issuance of ordinary shares	3,475	-	-	-	3,475	-	3,475	
Non controlling interests participation in equity of subsidiaries	-	-	-	-	-	2	2	
Total transactions with owners	3,475	-	-	-	3,475	2	3,477	
As at 31 Dec 2023	9,777	(1,450)	1	367	8,695	(27)	8,668	

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2023.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1ST HALF YEAR ENDED 30 JUNE 2024**CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**

	6 Months Ended 30 Jun 2024 (UNAUDITED) RM'000	12 Months Ended 31 Dec 2023 (AUDITED) RM'000
CASH FLOW FROM OPERATING ACTIVITIES		
(Loss)/Profit before taxation	(1,123)	966
Adjustments for:		
Depreciation of property, plant and equipment	373	608
Depreciation of right-of-use asset	152	328
Net allowance for expected credit losses	-	(132)
Amortisation of intangible assets	3	6
Share of associate's results	-	148
Interest expenses	230	420
Interest income	(9)	-
Fair value gain on financial assets at fair value through profit and loss	-	(6)
Gain on derecognition of lease liabilities	-	(48)
Gain on disposal of other financial assets	(12)	(37)
Operating (loss)/profit before working capital changes	(386)	2,253
Changes in working capital:		
Inventories	-	10
Trade & other receivables	(812)	(1,469)
Trade & other payables	(1,014)	(1,860)
Contract assets & liabilities	301	(875)
Contract costs	-	701
Amount owing to directors	8	-
	(1,517)	(3,493)
Cash used in operations	(1,903)	(1,240)
Interest received	9	-
Tax paid	(212)	(377)
	(203)	(377)
Net cash used in operating activities	(2,106)	(1,617)
CASH FLOW FROM INVESTING ACTIVITIES		
Investment in other financial assets	(2,038)	(4,500)
Proceeds from disposal of other financial assets	1,966	4,517
Additions in intangible asset	(689)	(527)
Additions to right of use assets	(152)	(64)
Purchase of property, plant and equipment (Advances to)/Repayments from:-	(343)	(647)
- An associate	-	(60)
- Subsidiaries of an associate	-	(10)
Net cash used in investing activities	(1,256)	(1,291)
CASH FLOW FROM FINANCING ACTIVITIES		
Interest paid	(230)	(420)
Drawdown of borrowings	760	121
Repayment of borrowings	(712)	(412)
Proceed/(Repayment) of lease liabilities	(83)	(341)
Advances from a corporate shareholder of a subsidiary	-	2,880
Proceeds from issuance of shares:-		
- Private Placement	1,887	3,475
- Non controlling interests	-	2
Net cash generated from financing activities	1,622	5,305
Net (decrease)/increase in cash and cash equivalents	(1,740)	2,397
Cash and cash equivalents at beginning of the period/year	2,405	6
Currency translation differences	(1)	2
Cash and cash equivalents at end of the period/year	664	2,405
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD/YEAR COMPRISES:		
Cash and bank balances	1,720	2,700
Less: Bank overdraft	(1,056)	(295)
	664	2,405

The Condensed Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2023.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED
30 JUN 2024**

**PART A: EXPLANATORY NOTES IN COMPLIANCE WITH MALAYSIAN FINANCIAL
REPORTING STANDARD (“MFRS”) 134: INTERIM FINANCIAL REPORTING**

A1) Basis of preparation

This interim financial statements have been prepared under the historical cost convention. This interim financial statements are unaudited and have been prepared in accordance with the requirements of Malaysian Financial Reporting Standards (“MFRS”) 134: Interim Financial Reporting and as well as Rule 6.12 and Appendix 6A of the LEAP Market Listing Requirements of Bursa Malaysia Securities Berhad (“Bursa Securities”).

The interim financial report should be read in conjunction with the Audited Financial Statements for the financial year ended 31 Dec 2023 and the accompanying explanatory notes attached to this interim financial report.

A2) Significant accounting policies and application of MFRS

The accounting policies adopted are consistent with those of the previous financial year except the amendments to following accounting standards that are effective for the Group’s financial year beginning on or after 1 Jan 2024:-

Description	Effective for annual periods beginning on or after
Amendments to MFRS 16: Lease Liability in a Sale and Leaseback	1 Jan 2024
Amendments to MFRS 101: Non-current Liabilities with Covenants	1 Jan 2024
Amendments to MFRS 107 and MFRS 7: Supplier Financing Arrangements	1 Jan 2024

The above amendments to accounting standards effective during the financial period do not have any significant impact on the interim financial report of the Group.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED
30 JUN 2024**

A2) Significant accounting policies and application of MFRS (Cont'd)

As at the date of authorisation of this Condensed Report, the following accounting Standards and amendments to accounting Standards have been issued by the Malaysian Accounting Standards Board ("MASB") but are not yet effective:-

Description	Effective for annual periods beginning on or after
Amendments to MFRS 121: The Effects of Changes in Foreign Exchange Rates - Lack of Exchangeability	1 Jan 2025
MFRS 18 Presentation and Disclosure in Financial Statements	1 Jan 2027

Effective date of these Amendments to Standards has been deferred, and yet to be announced:-

Amendments to MFRS 10 Consolidated Financial Statements and MFRS 128 Investments in Associates and Joint Venture – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture.

The above pronouncements are either not relevant or do not have any impact on the financial statements of the Group.

A3) Seasonal or cyclical factors

The Group's performance is not significantly affected by seasonal and cyclical factors.

A4) Unusual items

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the reporting period under review.



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUN 2024

A5) Material changes in estimates

There were no significant changes in the nature and amount of estimates reported in the prior interim period of the current financial period or prior years that have a material effect on the current financial period ended 30 Jun 2024 under review.

A6) Debt and equity securities

Saved as disclosed below, there were no issuance or repayment of debt and equity securities, share buy-backs, share cancellations, share held as treasury shares by the Group during the financial period:-

(a) 4,201,688 and 3,781,510 new ordinary shares were issued pursuant to the second and third tranche of the Private Placement, approved by shareholders at an extraordinary general meeting on 7 Nov 2023, at an issue price of RM0.238 per share which was listed on 2 Feb 2024 and 23 Feb 2024 respectively.

A7) Segmental reporting

The Group's segmental report for the current financial period ended 30 Jun 2024 under review are as follows:-

Revenue by Business Activities

	Individual 6 Months Ended		Cumulative Year To Date	
	30 Jun 2024 RM'000	30 Jun 2023 RM'000	30 Jun 2024 RM'000	30 Jun 2023 RM'000
<u>REVENUE</u>				
Provision of integrated turnkey solutions	247	2,152	247	2,152
Provision of maintenance services	543	525	543	525
Laboratory Services	1,980	1,813	1,980	1,813
Total consolidated revenue	2,770	4,490	2,770	4,490

A8) Valuation of property, plant and equipment

There was no valuation on any of the Group's property, plant & equipment during the reporting period ended 30 Jun 2024.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED
30 JUN 2024**

A9) Significant events

There were no events of a material nature to be disclosed in the interim financial statements for the current financial period ended 30 Jun 2024.

A10) Material changes in the composition of the Group

There was no changes in the composition of the Group during the reporting period ended 30 Jun 2024.

A11) Contingent liabilities and contingent assets

There were no material contingent liabilities or assets for the reporting period ended 30 Jun 2024.

A12) Material events subsequent to the end of the interim financial report

The management is not aware of any material events subsequent to the end of the interim financial report that have not been reflected in the financial statements for the current financial report ended 30 Jun 2024 under review, save and except for the followings:-

We refer to the announcements dated 4 August 2023, 4 September 2023, 17 October 2023, 15 November 2023, 23 November 2023, 24 November 2023, 19 January 2024, 31 January 2024, 2 February 2024, 14 February 2024, 22 February 2024, 23 February 2024 and 1 April 2024 as well as the Circular to shareholders dated 23 October 2023 in relation to the Private Placement.

The Board had on 2 Jul 2024 announced that Bursa Securities had vide its letter dated 28 Jun 2024, resolved to grant SuperGenics an extension of time till 15 October 2024 for the Company to complete the Private Placement.

A13) Capital commitment

There was no commitment for the purchase of property, plant and equipment provided for in the current financial report ended 30 Jun 2024.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1ST HALF YEAR ENDED
30 JUN 2024**

**PART B: ADDITIONAL INFORMATION REQUIRED UNDER THE LEAP MARKET LISTING
REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD**

B1) Review of performance

(i) 1st Half Year, FY 2024 (“H1FY2024”) vs 1st Half Year, FY 2023 (“H1FY2023”)

	INDIVIDUAL			CUMULATIVE		
	6 Months Ended		Variance	Year To Date		Variance
	30 Jun 2024	30 Jun 2023		30 Jun 2024	30 Jun 2023	
	RM'000	RM'000	%	RM'000	RM'000	%
Revenue	2,770	4,490	(38.3)	2,770	4,490	(38.3)
Gross profit	1,137	1,710	(33.5)	1,137	1,710	(33.5)
(Loss)/Profit before taxation	(1,123)	161	(797.3)	(1,123)	161	(797.3)

For the current financial period under review, the Group posted a revenue of RM2.77 mil as compared to its corresponding preceding financial period, H1 FY2023 of RM4.49 mil. Both maintenance services and laboratory services contributed 91.08% of the Group's revenue. Both revenues increased by a total of 7.91% from the corresponding preceding financial period mainly due to the increasing in number of services maintenance contract and laboratory services contract. The decline in project-based income which due to lesser number of projects awarded and completed for the reporting period has led to the reduced of group overall revenue.

With the impact of reduced in revenue of provision of integrated turnkey solutions, the Group has recorded loss before taxation of RM1.12 mil as compared to its corresponding preceding financial period H1 FY2023, for a profit of RM0.16mil.



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUN 2024

B1) Review of performance (Cont'd)

(i) Changes in revenue and LBT for H1FY2024 as compared with the immediate preceding period ended 31 Dec 2023 ("H2FY2023")

	Current 6 Months Ended 30 Jun 2024	Immediate 31 Dec 2023	Variance
	RM'000	RM'000	%
Revenue	2,770	5,747	(51.8)
Gross profit	1,137	2,938	(61.3)
(Loss)/Profit before taxation	(1,123)	805	(239.5)

The Group has recorded revenue of RM2.77 mil with loss before taxation of RM1.12 mil for the 1st half year ended 31 Dec 2024 as compared to the immediate preceding half year which recorded revenue of RM5.75 mil and profit before taxation of RM0.81 mil. The decline in revenue of both provision of integrated turnkey solutions as well as the laboratory services has led to the marked decline in profit before taxation as compared to the immediate preceding half year.

B2) Future prospects

The Malaysian economy advanced by 5.9% in the second quarter of 2024 (1Q 2024: 4.2%). The growth is driven by stronger domestic demand and further expansion in exports. Household spending increased amid sustained positive labour market conditions and larger policy support. Investment activity was underpinned by continued progress in multi-year projects and capacity expansion by firms. Exports improved amid higher external demand and positive spillovers from the global tech upcycle. Most supply-side sectors registered higher growth. The manufacturing sector was supported by broad-based improvement across all clusters, particularly in electrical and electronics (E&E). The services sector recorded strong growth, driven by consumer and business-related subsectors. On a quarter-on-quarter seasonally-adjusted basis, the economy expanded by 2.9% (1Q 2024: 1.5%).



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED
30 JUN 2024**

B2) Future prospects (Cont'd)

Headline and core inflation averaged 1.8% in the first half of 2024. During the quarter, both headline and core inflation edged higher to 1.9% (1Q 2024: 1.7% and 1.8% respectively). This was largely driven by higher housing and utilities inflation at 3.1% (1Q 2024: 2.6%). The share of Consumer Price Index (CPI) items recording monthly price increases was higher at 49.4% during the quarter (1Q 2024: 44.2%; second quarter average from 2011-2019: 43.9%), reflecting in part the price adjustments during the festive season and several policy measures by the Government during the period.

On the domestic front, household spending will be underpinned by continued employment and wage growth as well as policy measures. Investment activities will be driven by progress in multi-year projects across private and public sectors. Catalytic initiatives announced in national master plans and the higher realisation of approved investments are also key drivers for investment activities. Externally, the ongoing global tech upcycle and continued strong demand for non-electrical and electronics goods are expected to lift exports. Improvement in tourist arrivals and spending are expected to continue. Upside risks to growth include greater spillover from the tech upcycle, robust tourism activities, and faster implementation of existing and new investment projects. Downside risks to Malaysia's growth prospects stem from a downturn in external demand, an escalation in geopolitical conflicts and lower-than-expected commodity production.

Headline and core inflation are expected to edge higher in 2H 2024 mainly due to the rationalisation of diesel subsidies. However, the impact will remain manageable given mitigation measures by the Government to minimise cost impact to businesses. For the rest of the year, upside risks to inflation depend on the extent of the spillover effects from further domestic policy measures on subsidies and price controls to broader price trends, as well as global commodity prices and financial market developments. Overall, headline and core inflation for the year are projected to remain within the forecast ranges of 2.0% – 3.5% and 2.0% – 3.0% respectively.

(Source: Economic and Financial Developments in Malaysia in the Second Quarter of 2024, Bank Negara Malaysia)



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED
30 JUN 2024**

B2) Future prospects (Cont'd)

The Group is strategically expanding its presence throughout Southeast Asia, with a specific focus on emerging markets such as Indonesia, Vietnam, China, and the Philippines. Leveraging its expertise in upstream bioprocess design and training, the Group is dedicated to facilitating the establishment of biomanufacturing facilities for potential clients. Upon completion of these facilities which have been designed and proposed by the Group, clients will gain access to downstream cell-based products tailored to address various biotechnological needs.

Moreover, the Group is vigorously seeking avenues to advance its proprietary technologies, exemplified by the Supergenics' Laboratory Monitoring and Control System. This innovative system is tailored to address the distinct requirements of biomanufacturing facilities. Additionally, the Group has developed the Supergenics Modular Panel (SGMP), a cleanroom wall and furniture panel made from stainless steel, aluminum, or powder-coated mild steel.

In tandem with its traditional business operations, the Group's expansion into the Regenerative Treatment Segment is poised to significantly bolster its future prospects. Having successfully generated revenue from this segment since the fiscal year ending (FYE) 2021, the Group observed a remarkable doubling of revenue by FYE 2022. This growth underscores the segment's potential as a lucrative avenue for the Group's revenue streams.

Looking forward, the Group aims to further fortify its Regenerative Treatment Segment through strategic partnerships with service providers in the health, wellness, or aesthetic industries. By leveraging these partnerships, the Group seeks to increase product sales within this segment, penetrate new markets, and diversify its revenue streams.

The management of Supergenics holds an optimistic view of the Regenerative Treatment Segment's outlook, recognizing it as a rapidly growing sector with substantial potential to propel the Group's future growth trajectory. With a steadfast commitment to innovation and a keen eye on emerging trends in the healthcare industry, the Group is poised to harness the opportunities presented by this dynamic market segment, thereby delivering sustained value to its stakeholders.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED
30 JUN 2024**

B3) Profit forecast, Profit Guarantee and Internal Targets

The group has not issued any profit forecast, profit guarantee in any form of public documentation and announcement.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED
30 JUN 2024**

PART C: OTHER INFORMATION

C1) Status of Corporate Proposal

Save as disclosed below, there were no other corporate proposals announced but pending completion as at the date of this report:-

- i) The Company had on 4 Aug 2023 announced the private placement of up to 26,000,000 new ordinary shares in the Company, representing approximately 27.96% of the existing total number of issued shares of the Company at an issue price to be determined and announced later ("Private Placement") and the diversification of the principal activities of the Company and its subsidiaries to include the provision of administrative health care services, operating of medical laboratories and development of regenerative treatment products for medical treatment and wellness ("Diversification"). Shareholders' approval for the Private Placement and Diversification were obtained at the extraordinary general meeting held on 7 Nov 2023.

The Board had on 15 Nov 2023 fixed the issue price for the 1st tranche of the Private Placement comprising 14,705,883 Placement Shares at RM0.238 per share which was listed on the LEAP Market of Bursa Securities on 24 Nov 2023.

The Board had on 19 Jan 2024 fixed the issue price for the 2nd tranche of the Private Placement comprising 4,201,688 Placement Shares at RM0.238 per share which was listed subsequently on 2 Feb 2024.

Subsequently on 14 Feb 2024, the Board had fixed the issue price for 3rd tranche of the Private Placement comprising 3,781,510 Placement Shares at RM0.238 per share which was completed and listed on 23 Feb 2024.

The Board had on 2 Jul 2024 announced that Bursa Securities had vide its letter dated 28 Jun 2024, resolved to grant Supergenics an extension of time till 15 October 2024 for the Company to complete the Private Placement exercise whereby there are up to 3,310,919 shares to be issued at an issue price to be determined and announced later.



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUN 2024

C2) Material Litigation

The management is not aware of any pending material litigation which will have a material effect on the financial position or the business of the Group and the Board is not aware of any proceedings pending or threatened against the Group or of any fact likely to give rise to any proceedings which may materially and adversely affect the financial position or business of the Group at the date of this report.

C3) Dividends

No dividend has been declared by the Group since the end of the previous financial year. The Board of Directors do not recommend any dividend in respect of the current financial period under review.

C4) Utilisation of Proceeds

The proposed utilization of proceeds from the fund raising of RM 6.0 mil are as follows:-

Description	Proposed Utilisation RM'000	Actual Utilisation RM'000	Balance RM'000	Timeframe for Utilisation Upon Listing
(I) Manufacturing of the SGMP	2,000	(1,730)	270	12 months
(II) R&D of technology used in the production of regenerative treatment products	2,000	(1,126)	874	12 months
(III) Repayment of bank borrowings	1,200	(1,194)	6	6 months
(IV) Working capital	706	(705)	1	6 months
(V) Estimated expenses	100	(100)	-	Immediate
	6,006	(4,855)	1,151	

Note:-

(1) As at the date of this report, the actual gross proceeds raised from the Private Placement were RM5.4 Mil, and total of 22,689,081 new ordinary shares were issued at an issue price of RM0.238 per share.

(2) The Company was granted an extension of time till 15 October 2024 to complete the Private Placement exercise whereby there are up to 3,310,919 shares to be issued at an issue price to be determined and announce later.

(3) The actual utilisation is up to the date of this report.



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUN 2024

C5) Earnings per share

	Individual 6 Months Ended		Cumulative Year To Date	
	30 Jun 2024	30 Jun 2023	30 Jun 2024	30 Jun 2023
a) <u>Basic earnings per-share</u>				
(Loss)/Profit attributable to the owners of parent ('000)	(988)	47	(988)	47
Total weighted average number of ordinary shares in issue ('000)	113,728	93,000	113,728	93,000
Basic earning per share (sen)	(0.87)	0.05	(0.87)	0.05
b) <u>Diluted earnings per-share</u>	N/A	N/A	N/A	N/A

C6) Authorisation for issue

The interim financial report were authorised for issue by the Board of Directors in accordance with resolution of the directors.